In contrast to the poor outcomes of these direct TNFα suppression, interferon (IFN) β [38,39] and glatiramer acetate (GA) [40,41] have been widely approved as effective immunomodulatory treatments for MS. This evidence concerns the gene TNF and myeloid sarcoma.